RESEARCH ARTICLE

Microbial and metabolomic remodeling by a formula of Sichuan dark tea improves hyperlipidemia in apoE-deficient mice

Lingzhi Li¹, Min Shi¹, Stephen Salerno², Minghai Tang¹, Fan Guo¹, Jing Liu¹, Yanhuan Feng¹, Martina Fu², Qinwan Huang³, Liang Ma¹*, Yi Li², Ping Fu¹*

¹ Division of Nephrology and National Clinical Research Center for Geriatrics, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, China, ² Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan, United States of America, ³ College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China

* liang_m@scu.edu.cn (LM); fupinghx@scu.edu.cn (PF).

Abstract

Medicine-food homology is a long-standing concept in traditional Chinese medicine. YiNian-KangBao (YNKB) tea is a medicine-food formulation based on Sichuan dark tea (Ya’an Tibetan tea), which is traditionally used for its lipid-lowering properties. In this study, we evaluated the effects of YNKB on dyslipidemia and investigated the mechanism underlying its correlation with gut microbiota and serum metabolite regulation. Wild-type mice were fed a normal diet as a control. Male ApoE-/- mice were randomly divided into three high-fat diet (HFD) groups, a model group, and two treated groups (100, 400 mg/kg/d for low, high-dose), and fed by gavage for 12 weeks. Serum lipid levels, composition of gut microbiota, and serum metabolites were then analyzed before treatment with YNKB. We extracted the ingredients of YNKB in boiled water for one hour. YNKB supplementation at a high dose of 400 mg/kg/day reduced bodyweight gains (relative epididymal fat pad and liver weight), and markedly attenuated serum lipid profiles and atherosclerosis index, with no significant differences present between the low-dose treatment and HFD groups. Gut microbiota and serum metabolic analysis indicated that significant differences were observed between normal, HFD, and YNKB treatment groups. These differences in gut microbiota exhibited strong correlations with dyslipidemia-related indexes and serum metabolite levels. Oral administration of high-dose YNKB also showed significant lipid-lowering activity against hyperlipidemia in apoE-deficient mice, which might be associated with composition alterations of the gut microbiota and changes in serum metabolite abundances. These findings highlight that YNKB as a medicine-food formulation derived from Sichuan dark tea could prevent dyslipidemia and improve the understanding of its mechanisms and the pharmacological rationale for preventive use.

Introduction

Hyperlipidemia is a major risk factor contributing to atherosclerosis and cardiovascular disease (CVD). It is characterized by abnormal plasma lipid levels, including increased...
triglyceride (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c), and decreased high-density lipoprotein cholesterol (HDL-c) [1, 2]. Regulating lipid metabolism disorders is a potential approach to slowing or preventing the development of CVD. Although medications such as fibrates and statins are effective in the treatment of lipid metabolism dysfunction, their use is limited by individual differences in hyperlipidemia patients, drug dependence, and potential adverse effects including liver and kidney dysfunction, myopathy, and rhabdomyolysis [3–5].

Traditional herbal remedies with multi-functional nutrients, known as “Medicine-food homology” or “Affinal Drug and Diet,” have evolved from ancient healing systems and have enjoyed a remarkable resurrection in recent years [6, 7]. Sichuan dark tea, one of China’s dark tea representatives, is a popular medicine-food beverage for ethnic groups living in the regions of Sichuan and Tibet. It is fermented from the rough old leaves of *Camellia sinensis* with various microorganisms. Recently, considerable studies have focused on the pharmacological activity of Chinese dark tea, which has been traditionally used in drug formulations or as food for the prevention and treatment of hyperlipidemia, obesity, and diabetes [8–11].

In accordance with the theory of traditional Chinese medicine (TCM) and guidelines set by the Chinese Food and Drug Administration (CFDA) surrounding the use of foods for special medical purpose, YiNianKangBao (YNKB), as a homology of medicine and food based on Sichuan dark tea, was developed and used on the market for the preventive treatment of dyslipidemia. Specifically, sixteen traditional Chinese herbs (S1 Table), which have been reported to alleviate hyperlipidemia, atherosclerosis, and cardiovascular diseases [12–16], were formulated in a mixture with Sichuan dark tea for optimal compatibility. However, the anti-hyperlipidemic activity of YNKB and its potential mechanisms are unclear. Hence, in this study, the water extract of medicine-food YNKB was prepared and first evaluated in high-fat diet (HFD) induced apoE-deficient mice. The potential lipid-lowering function of YNKB involved in the modulation of gut microbiota composition and serum metabolite levels was also investigated.

**Materials and methods**

**Preparation of medicine-food YNKB extract**

YNKB, produced by the Chengdu YiNianKangBao Biological Technology Co., Ltd. (Chengdu, China), consists mainly of Sichuan dark tea, *Nelumbo nucifera* Gaertn., *Crataegus pinnatifida* Bge, *Lycium barbarum* L., and *Morus alba* L. (see S1 Table for the full display of ingredients). These components were accredited according to the Pharmacopoeia of the People’s Republic of China (2015 edition). After being fully mixed, the medicine-food ingredients were boiled twice with hot water (1L × 2), followed by filtration processes. The filtered solution containing the extract was then evaporated as YNKB for the in vivo experiment. High-performance liquid chromatography-mass spectrometry (HPLC-MS) analysis of YNKB tea is shown in S1 Fig. As the recommended dose of YNKB tea for human was 2g per day from the instruction, we converted the dose from human to mouse as a high-dose of 400mg/kg/d according to the published article [17]. Additionally, from other articles, 100mg/kg/d herbal administration showed significant antihyperlipidemic effects [18], which suggested to us to add 100mg/kg/d as the low-dose group.

**Experimental design**

Seven male wild-type mice and 20 male ApoE-/- mice were obtained from the Animal Laboratory Center of Sichuan University (Chengdu, China) at 10 weeks of age. The mice were housed in a room under a 12:12-hour light-dark cycle with free access to food pellets and water. After two weeks of acclimatization with the standard chow diet, the ApoE-/- mice were then
randomly assigned into three groups and fed with a 40% HFD (D12451, Research diet, New Brunswick, NJ, USA) and 0.9% saline solution for 12 weeks by gavage. The three ApoE-/- mice groups were randomized to receive just the HFD (HFD group), the HFD and a low-dose of YNKB (100 mg/kg/day; HFD+L group), or the HFD and a high-dose of YNKB (400 mg/kg/day; HFD+H group). The wild-type mice continued to be administered a standard chow diet as control (N group; D12450B, Research diet, New Brunswick, NJ, USA). See S2 Table for full details. The body weights of the mice and food intake were measured every week. After 12 weeks, all mice were euthanized by applying pentobarbital through intraperitoneal injection and samples were collected. The epididymal fat pad, liver, kidney, heart, aorta and ileum content were excised, weighed, and frozen in liquid N\textsubscript{2} or stored in 10% neutral formalin. A viscerum index (including relative epididymal fat pad weights and relative liver weight) was calculated using the formula: organ weight/body weight (mg/g). The protocol was approved by the animal ethics committee of Sichuan University (No. 2017080A).

**Measurement of blood biochemical indices**
Serum levels of TC, TG, HDL, aspartate transaminase (AST) and alanine transaminase (ALT) were determined using a kit from BioSino Biotechnology & Science Inc. (Beijing, China).

**Histopathological analysis of the liver**
Freshly isolated livers were fixed in 10% formalin for 24 hours prior to histopathological evaluation. After being rinsed under running water, the tissues were processed in a paraffin automatic processor using a programmed cascade. Paraffin-embedded liver tissues were dissected (4μm thick) and stained with hematoxylin and eosin. After staining, histopathological features were assessed under a microscope. One photograph per sample was obtained using both a 200x and 400x optical microscope.

**Determination of lipid levels in liver tissue**
Hepatic TC and TG contents were determined using commercially available kits from BioSino Biotechnology & Science Inc. (Beijing, China).

**16S rRNA gene sequencing**
Microbial DNA was extracted from ileum content samples using the E.Z.N.A. DNA Kit (Omega Bio-tek, Norcross, GA, U.S.) according to the standard protocol. The V3-V4 hyper-variable regions of the bacteria 16S rRNA gene were amplified with primers 338F (5’-ACT CCTACGGGAGGCAGCAG-3’) and 806R (5’-GGACTACHVGGGTWTCTAAT-3’) by thermocycler PCR. Purified amplicons were pooled and paired-end sequenced (2 × 300) on an Illumina MiSeq platform (Illumina Inc., San Diego, CA, USA) according to the standard protocols. All raw reads were screened according to barcode and primer sequences, using Quantitative Insights Into Microbial Ecology (QIIME, version 1.17), with the following criteria. (1) The reads were truncated at any site receiving an average quality score < 20 over a 50 bp sliding window. (2) Primers were exactly matched, allowing for 2 mismatched nucleotides, and reads containing ambiguous bases were removed. (3) Sequences with overlaps longer than 10 bp were merged according to their overlap sequence. Operational taxonomic units (OTUs) were clustered with a cut-off of 97% similarity using UPARSE (version 7.1), and UCHIME was utilized to identify and remove chimeric sequences. The raw reads were deposited into the NCBI Sequence Read Archive (SRA) database (Accession Number: SRR9028650).
Serum metabolomic analysis

200 μL of each sample were thawed at 4°C, transferred into a centrifugal tube together with 800 μL of methanol, and mixed by vortexing for 60s. After centrifuging at 12,000 rpm for 10 minutes, the supernatant in each tube was transferred to another tube. The samples were blow-dried in vacuum, dissolved in a 300 μL methanol aqueous solution (4:1, 4°C), and filtered through a 0.22 μm membrane. HPLC-MS sample extracts were then obtained. 20 μL of each prepared sample extraction were taken for quality control (QC), and the rest were carried forward for HPLC-MS testing. Chromatographic separation was accomplished in an Acquity UPLC system equipped with an ACQUITY UPLC BEH C18 (100×2.1 mm, 1.7 μm, Waters) column maintained at 4°C. Gradient elution of analytes was carried out with 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B) at a flow rate of 0.25 mL/min. Injections of 5 μL of each sample were done after equilibration. An increasing linear gradient of solvent B (v/v) was used as follows: 0~1min, 2%; 1~9.5min, 2%~50%; 9.5~14min, 50%~98%; 14~15min 98%; 15~15.5min, 98%~2%; 15.5~17min, 2%. The ESI-MS experiments were executed on the Thermo LTQ-Orbitrap XL mass spectrometer with a spray voltage of 4.8kV and -4.5kV in positive and negative modes, respectively. Sheath gas and auxiliary gas were set at 45 and 15 arbitrary units, respectively. The voltages of the capillary and tube were 35V and 50V, and -15V and -50V in the positive and negative modes, respectively. The Orbitrap analyzer scanned over a mass range of m/z 89–1000 for the full scan at a mass resolution of 60000. Data dependent acquisition (DDA) MS/MS experiments were performed with CID scan. The normalized collision energy was 30eV. Dynamic exclusion was implemented with a repeat count of 2 and exclusion duration of 15s.

Statistical analysis

Statistical analysis was carried out in the SPSS 22.0 software (SPSS Inc., Chicago, IL, USA) and R, version 3.3.2. Statistical comparisons were assessed with a one-way ANOVA and Student’s t-test for each paired experiment, and the Wilcoxon rank sum test was used to analyze data that did not meet the assumptions of the Student’s t-test. The beta diversity of gut microbiota was assessed by a metric multidimensional scaling method based on a projection known as principal coordinates analysis (PCoA). Each sample was mapped based on the overall microbial composition and assessed for similarities. The specific characterization of fecal microbiota to distinguish taxonomic types was analyzed by the linear discriminant analysis (LDA) effect size (LEfSe) method. Using a normalized relative abundance matrix, LEfSe performs the Kruskal-Wallis rank sum test to determine the features with significantly different abundances between assigned taxa and uses LDA to assess the effect size of each feature. Correlations between abundances of gut microbiota, hyperlipidemia-related indexes, and serum metabolites were identified using Spearman’s correlation and visualized by heatmap. The PICRUSt package was used to construct the Kyoto Encyclopedia of Genes and Genomes (KEGG) Orthology (KO) and KEGG pathway/module profile, predicting functional profiling of microbial communities using 16S rRNA marker gene sequences. The pathway set enrichment analyses were performed using Metabolanalyst (www.metabolanalyst.ca) to elucidate the metabolic pathways affected by metabolite distinctions among hyperlipidemia ApoE-/- mice and the treated groups. P-values less than 0.05 were regarded as significantly different.

Results

High-dose YNKB attenuated bodyweight, hyperlipidemia and fatty liver in HFD-induced ApoE-/- mice

After 12 weeks, the HFD group gained significantly more weight than the normal (N) group (p < 0.0001; Fig 1A). The high-dose treatment (HFD+H) group was shown to decrease
bodyweight gains in the HFD-induced ApoE−/− mice (p < 0.05), while the low-dose treatment (HFD+L) group showed no significant difference when compared to the HFD group (Fig 1B). As indicated by the percentage of body weight, the epididymal fat pad and liver weighed more in the HFD group than in the N group (Fig 1C and 1D). Additionally, the relative epididymal
fat pad weights in the high-dose treated HFD+H group decreased slightly, while the relative liver weight was significantly reduced when compared to the HFD group (p < 0.05).

With respect to the serum lipid indexes, the ApoE-/- mice in the HFD group developed remarkable features of hyperlipidemia, with a significant increase in the TG concentration (p < 0.05), TC concentration (p < 0.001), and atherosclerosis index (p < 0.001; Fig 1E–1H). The HFD+H group exhibited lowered TG levels and atherosclerosis index and increased HDL concentration. However, no differences in serum TC concentration were observed after 12 weeks of YNKB treatment. AST and ALT levels showed no differences among the four groups (Fig 11 and 1I). Altogether, these results suggested that the high-dose tea treatment significantly alleviated HFD-induced weight gains and hyperlipidemia.

The high-fat diet markedly increased hepatic TC and TG levels (Fig 1K and 1L). However, the increases in hepatic TC and TG were significantly attenuated by the high-dose tea administration when compared with the HFD group (p < 0.0001; Fig 1K and 1L). The high-fat diet induced lipid accumulation in hepatic tissue, as evidenced by HE staining in the HFD group, was also significantly ameliorated by tea treatment (Fig 1M).

Transmissible microbial remodeling by hyperlipidemia and YNKB treatment

Due to the deficiency of ileum content in HFD-fed ApoE-/- mice, nineteen mice were included in the microbiota analysis. A total of 514 OTUs were obtained at a 97% homology cutoff. Alpha diversity curves indicated that a significant increase in richness, measured by the Chao index, was observed in the HFD group compared to the N group at OTU level (Fig 2A and 2B). However, the treatment of YNKB decreased the richness of bacterial communities. The diversity of the microbial communities, measured by the Shannon diversity indices, was

Fig 2. Microbiota changes in the composition of HFD-induced ApoE-/- mice by YNKB. The rarefaction curves of alpha diversity ((A) Ace, (B) Chao, or (C) Shannon index); (D) Venn diagram of the OTUs in the three groups; The beta diversity as measured by (E) hierarchical clustering tree and (F) unweighted Unifrac PCoA analysis.

https://doi.org/10.1371/journal.pone.0219010.g002
decreased in the HFD group compared to the N group, while treatment restored bacterial diversity in the HFD+L and HFD+H groups (Fig 2C). 173 OTUs were shared by all groups (Fig 2D).

The overall compositions of gut microbiota in the four groups at the phylum level were analyzed via hierarchical clustering tree and unweighted unifrac principal coordinates analysis at the OTU level (Fig 2E and 2F). The different doses of YNKB were shown to shift the overall compositions of the gut microbiota in the HFD group toward the composition of the normal diet group.

Results of the taxon-based analysis revealed that the gut microbiome consisted of five dominant phyla: Firmicutes, Actinobacteria, Bacteroidetes, Proteobacteria, and Verrucomicrobia (Fig 3A). After 12 weeks of a HFD in ApoE-/- mice, widespread changes in the structure of gut microbiota were observed at the phylum level, with significantly increased proportions of Firmicutes and decreased proportions of Actinobacteria, Bacteroidetes, and Verrucomicrobia. The different doses of YNKB treatment attenuated the changes in the gut microbiota structures by decreasing proportions of Firmicutes and increasing proportions of Actinobacteria, Verrucomicrobia, and Bacteroidetes (Fig 3B).

---

**Fig 3. Effects of YNKB on gut microbiota relative proportion in HFD-induced ApoE-/- mice at phylum level.**

(A) The main microbiota and their relative proportions in different groups. Data are presented as means. The top five and fifteen microbiotas and their relative proportions in different groups at phylum level (B) and genus level (C). Differences in dominant microorganisms among groups were shown in (D) Cladogram and (E) Distribution histogram based on LDA. *p<0.05, **p<0.01 among the four groups.

https://doi.org/10.1371/journal.pone.0219010.g003
Table 1. The changes of the top fifteen genera by the treatment of YNKB.

| Genus                  | HFD ratio (%) | N ratio (%) | HFD+L ratio (%) | HFD+H ratio (%) |
|------------------------|---------------|-------------|-----------------|-----------------|
| Corynebacterium_1      | 5.83±8.35     | 18.33±16.49 | 7.97±11.51      | 16.27±11.41     |
| Turicibacter           | 8.17±7.08     | 5.94±5.20   | 4.63±6.41       | 17.74±20.48     |
| Lactobacillus          | 7.97±9.68     | 15.69±22.36 | 1.80±0.72       | 8.77±12.18      |
| Faecalibaculum         | 6.74±8.89     | 13.77±15.42 | 6.64±4.61       | 6.40±13.85      |
| Romboutsia             | 13.35±8.55    | 0.11±0.14   | 5.93±4.79       | 10.69±12.95     |
| norank_f_Erysipelotrichaceae | 1.43±1.65 | 4.6±5.01    | 16.2±11.19      | 3.5±7.44        |
| Bifidobacterium        | 2.83±2.67     | 14.18±15.44 | 4.64±4.77       | 3.3±5.15        |
| Clostridium_sensu_stricto_1 | 20.58±19.41 | 0.40±0.38  | 2.07±2.00       | 0.86±0.92       |
| Streptococcus          | 5.94±5.04     | 3.14±4.87   | 2.26±1.58       | 1.20±12.37      |
| norank_f_Bacteroidales_S24-7_group | 1.24±1.27 | 6.27±7.37  | 5.92±5.17       | 3.34±5.38       |
| unclassified_f_Lachnospiraceae | 0.77±1.21 | 0.08±0.079 | 11.35±11.35*    | 0.05±0.07       |
| Candidatus_Arthromitus | 11.26±17.6    | 0*          | 0.34±0.87*      | 0.0005±0.001*   |
| Akkermansia            | 0.017±0.030   | 1.04±2.13   | 7.53±5.428*     | 1.04±2.64       |
| Aerococcus             | 1.09±1.98     | 5.13±5.83   | 0.22±0.24       | 1.95±2.85       |
| Escherichia-Shigella   | 0.017±0.027   | 2.12±3.66   | 3.96±9.98*      | 0.31±0.38*      |

*p<0.05 versus model group.

https://doi.org/10.1371/journal.pone.0219010.1001

Among the top fifteen abundant genera, the relative abundances of Romboutsia (p<0.01) and Candidatus Arthromitus (p<0.001) were significantly increased in the HFD group compared to those of the normal diet group, while Akkermansia (p<0.01) and Escherichia-Shigella (p<0.05) abundances were considerably decreased (Fig 3C, Table 1). Other genera such as Lactobacillus and Bifidobacterium also showed a trend in reduction, though without a statistic difference. The YNKB treatment, especially at the high-dose level, significantly restored the abundance of several genera such as Candidatus Arthromitus (p<0.05), Akkermansia (p<0.05) and Escherichia-Shigella (p<0.05) (Fig 3C, Table 1).

To further identify the specific bacterial taxa associated with dyslipidemia, the compositions of the fecal microbiota for the ApoE-/- mice and healthy controls are displayed in Fig 3D. The differences in the taxa between these groups were also compared. In total, the LEfSe analysis revealed 76 discriminative features (LDA > 3, Fig 3E). Taken together, these data indicated that the ApoE-/- mice treated with YNKB had different abundance levels of certain bacteria in the gut microbiota when compared to the N and HFD groups.

Specific microbial taxa were associated with the features of hyperlipidemia

Correlations between the shift of microbiota and clinical biomarkers were analyzed using Pearson correlation analysis. At the phylum level, Actinobacteria, Synergistetes, and cyanobacteria showed strong negative correlations with the hyperlipidemia index (Fig 4A). At the class level, Epsilonproteobacteria, Clostridia, and Alphaproteobacteria exhibited robust positive correlations with pre-post weight gains, relative epidydimal fat pad weights, and relative liver weights, while Negativicutes, Actinobacteria, cyanobacteria, TK10 and Synergistetes showed opposite relationships (Fig 4B). At the genus level, Enterococcus, Glutamicibacter, Aerococcus, Vagococcus, and Proteus showed negative correlations with weight gains or relative organ weights, among which Vagococcus and Proteus showed the strongest negative associations.
Trichococcus, Vagococcus, unclassified_o_Lactobacillales, Thermocirga, and Proteus showed negative associations with TC or TG. However, there were more genera illustrating positive
correlations with these hyperlipidemia-related indexes, including *Paresutterella*, *Atopostipes*, *Coprococcus-1*, *Ruminococcaceae-UG-004*, unclassified_f_Lachnospiraceae, *Ruminiclostridium-5*, *Sporosarcina*, *Candidatus Arthromitus*, *Helicobacter*, *Actinomyces*, *Romboutsia*, and others. (Fig 4C). Among these genera, *Romboutsia*, unclassified_f_Lachnospiraceae, *Candidatus Arthromitus*, and *Helicobacter* were significantly increased in the HFD group and reversed by YNKB treatment (Table 1). These findings indicate that the alterations of gut microbiota induced by YNKB are associated with hyperlipidemia-related markers.

Pronounced metabolomic shift in response to hyperlipidemia and YNKB treatment

The PCA score plots and quality control (QC) results are shown in Fig 5A. A total of 2,343 metabolites (947 in the negative ion mode, 1398 in the positive ion mode) were detected in the

![PCA plot](https://doi.org/10.1371/journal.pone.0219010.g005)
N, HFD, HFD+L and HFD+H groups. To investigate the global metabolite profiles, we used an FDR-corrected p-value < 0.05 as the threshold for statistical significance in the present study. Four metabolites were found to be differentially abundant in the HFD groups, with levels restored by YNKB administration. As shown in the box plots (Fig 5B), the levels of LysoPE (22:4(7Z,10Z,13Z,16Z)/0:0) and LysoPC(20:4(8Z,11Z,14Z,17Z)) were reduced significantly in the HFD samples, when compared to the normal samples. However, 11,14,17-Eicosatrienoic acid and 1-octadecylglycerol-3-phosphocholine levels were increased significantly in the HFD group compared to the normal group. High-dose treatments with YNKB were shown to potentially restore these changes.

After analyzing the correlations between the four metabolites and gut microbiota at the genus level (Fig 5C), we found that the genera (Enterococcus, Glutamicibacter, Aerococcus and Trichococcus) showed negative correlations with hyperlipidemia-related parameters, had strong positive correlations with LysoPE(22:4(7Z,10Z,13Z,16Z)/0:0) and LysoPC(20:4(8Z,11Z,14Z,17Z)), and were negatively correlated with 11,14,17-Eicosatrienoic acid and 1-octadecylglycerol-3-phosphocholine. However, there were more genera which illustrated positive correlations with these hyperlipidemia-related indexes (including Paresutterella, Coprococcus-1, Ruminococcaceae-UCG-004, unclassified_f_Lachnospiraceae, Ruminiclostridium-5, Sporosarcina, Candidatus Arthromitus, Helicobacter, Actinomyces, and Romboutsia), which also had negative relationships with LysoPE(22:4(7Z,10Z,13Z,16Z)/0:0) and LysoPC (20:4(8Z,11Z,14Z,17Z)), and positive correlation with 11,14,17-Eicosatrienoic acid and 1-octadecylglycerol-3-phosphocholine.

The pathway set enrichment analyses were performed using Metabolanalyst (www.metabolanalyst.ca) to elucidate the metabolic pathways affected by metabolite distinctions between the normal, HFD, and YNKB treatment groups. The comparison between the N and HFD groups revealed pertubations of 13 networks, among which glycerophospholipid metabolism had the highest pathway impact (Fig 5D). When comparing the HFD and YNKB treatment groups, we found that low-dose YNKB treatment mainly influenced phenylalanine metabolism and valine, leucine, and isoleucine biosynthesis metabolism (Fig 5E), while a high-dose of YNKB primarily impacted phenylalanine metabolism and glycerophospholipid metabolism (Fig 5F).

**Discussion**

In this study, the high-dose YNKB treatment provided significant and meaningful reductions in physical measures (pre-post body weight gains, relative epididymal fat pad weights, and relative liver weights), biochemical indexes (TC, TG, and atherosclerosis index), and hepatic lipid accumulation when compared to those of the HFD group. Additionally, the HDL level was significantly improved after YNKB treatment. Although the benefits of YNKB have not been previously reported, the lipid lowering benefits of these major components have all been described and confirmed in previous studies. *Nelumbo nucifera* Gaertn., one of the major components, was beneficial for the suppression of obesity by inhibiting the absorption of lipids and carbohydrates, accelerating lipid metabolism, and up-regulating energy expenditure [16]. Additionally, *Nelumbo nucifera* Gaertn. was shown to successfully ameliorated type 2 [19] or type 1 diabetes mellitus progress and its complications [13]. *Morus alba* L. and *Lycium barbarum*, other commonly utilized traditional Chinese herbs, were indicated to reduce the concentration of fasting glucose, TG, TC, and atherosclerotic lesion development in experimental studies [20, 21] and clinical research [22]. *Lycium barbarum* was also reported to be effective in the protection of liver and kidney tissue from damage in STZ-induced diabetic rats [23]. Additionally, the extracts from the *Morus alba* L. fruit and Hawthorn are capable of decreasing
glucose production and triacylglycerol synthesis, which have antidiabetic and antihyperlipi-
demic benefits [12, 24, 25].

With respect to gut microbiota, several previous studies mentioned the importance of the ileum on the control of metabolic disease and bacterial translocation [26–28]. It was even found that drastic changes in the intestinal immune system occur in the ileum, rather than in the colon, in response to a fat-enriched diet, which suggested that the bacteria interacting with the host could be distributed locally rather than widely throughout the gut [26]. According to these previous studies, we choose the ileum contents to test microbiota alteration. Recent studies regarding the green and black tea polyphenols illustrated that tea could influence the structure of gut microbiota [29]. However, YNKB, as drug homologous food, has never been reported to alter microbiota composition. In this study, we found that the microbiota diversity of the HFD group decreased significantly, which was consistent with a previous study showing the lower diversity in obese patients compared to lean individuals [30, 31]. After treatment with YNKB, the decline in microbiota diversity was significantly reversed. With the highly diverse gut microbial environment, microbes will prefer to spend resources on competing and cooperating, rather than on manipulating their hosts, and hosts were indicated to be more resistant to invasion by pathogenic species [32, 33]. As to Fig 2F, we found that the HFD+L group seemed more effective in shifting the gut microbiota compositions toward the composition of the N group. This result was consistent with previous studies, which found that medium doses of resveratrol, rather than high doses, induced more obvious shifts in gut microbiota composition according to principal component analysis [34] and the highest richness was observed for the low violacein group, followed by the high violacein group and then the control group [35]. It is possible that the results might be influenced by the small sample size in these animal studies. However, we still have no evidence to explain this phenomenon. Similar to previous experiments, not only did the diversity of the microbiota change, but the structure of the microbiota in the HFD group was also converted, presenting obesity-like gut microbiota composition with increased Firmicutes and decreased Bacteroidetes and Bifidobacterium [36]. An increased abundance of Firmicutes was related to the accumulation of lipid droplets, promoting fatty acid absorption in the initiation of obesity and atherosclerosis [37–39]. Bifidobacterium and Lactobacillus, as the beneficial taxa, may contribute to the significant reduction of serum lipids and the alleviation of characteristic parameters of metabolic syndrome [40, 41]. Due to these previous studies, we hypothesize that the increasing diversity and changing composition of gut microbiota by YNKB will help to attenuate hyperlipidemia. However, the detailed mechanism remains to be further explored.

In order to determine the specific microbiota influencing hyperlipidemia, we focused our analysis at the genus level and found that concentrations of Clostridium sensu stricto 1, Romboutsia, and Candidatus Arthromitus increased significantly in HFD group, as compared with those of N group, while the concentrations of Akkermansia, and Escherichia-Shigella significantly decreased. After YNKB administration, the concentrations of Akkermansia, Escherichia-Shigella, and Candidatus Arthromitus were restored following the improvement of hyperlipidemia features. Today, growing evidence indicates that the increased intestinal abundance of Akkermansia protects against obesity-linked metabolic syndrome [42, 43] and contributes to the beneficial metabolic effects of the antidiabetic drug metformin [44–46] by restoring the decreased mucus layer and improving gut permeability [47]. These conclusions are consistent with our findings. Streptococcus, enriched by high-dose YNKB in our study, also successfully decreased serum cholesterol levels in the other hyperlipidemia rats accompanied with Lactobacillus [48]. However, Escherichia-Shigella, a genus which was once reported to be positively associated with necrotizing enterocolitis [49], was decreased markedly in our model group and was reversed by the YNKB therapy.
In addition, we found several bacterial taxa in the gut correlated with the hyperlipidemia biomarkers, including both physical and biochemical indices. We note that the proportions of Clostridium, Candidatus Arthromitus, and Romboutsia were positively correlated with weight gains and gains in relative organ weights. After YNKB treatment, the concentration of Clostridium sensu stricto 1 and Candidatus Arthromitus dramatically dropped, characterizing a reverse in hyperlipidemia, which was consistent with these previous findings [50]. These microbiota functions might be associated with gut permeability, as Clostridium was reported to contribute to infection of necrotizing enterocolitis [49]. We also discovered that Cyanobacteria, Vagococcus, Proteus, Aerococcus, and Enterococcus showed strong negative correlations with hyperlipidemia indexes, which were reported before or newly announced [51, 52].

Data on gut microbiota perturbations associated with metabolic phenotype changes have been used to understand the possible mechanisms in the development of diseases such as obesity and hepatopathy [53, 54]. Herein, we performed serum metabolic analysis and observed a significant correlation between gut microbiota genus and serum metabolites using Spearman’s correlation analysis. We found that the serum metabolic profile of dyslipidemia ApoE-/- mice was significantly different from that of the normal controls. The concentrations of the four significantly altered metabolites, LysoPE (22:4(7Z,10Z,13Z,16Z)/0:0), LysoPC(20:4 (8Z,11Z,14Z,17Z)), 11,14,17-Eicosatrienoic acid, and 1-octadecylglycerol-3-phosphocholine, displayed strong correlations with several microbiota, including Candidatus Arthromitus and Romboutsia, which were also strongly connected with dyslipidemia-related indexes. Previous studies mentioned that LysoPC and LysoPE, which are structural components of animal cell membranes, are decreased in acute liver injury, acute coronary syndrome, fetal congenital heart defect, and schizophrenia [55–57] and could be identified as biomarkers for progression from early to advanced aristolochic acid nephropathy and advanced aristolochic acid nephropathy [58]. In children with substantial weight loss, LysoPC (20:4) increased significantly with increased lipolysis and a lower rate of fatty acid oxidation [59], which was consistent with our findings. Octanoylcarnitine was also reported to increase in obese adolescents when compared to non-obese adolescents [60] and change in the presence of other diseases as well [61]. These findings support the beneficial effects of these microbiota changed by YNKB and the associations of altered metabolites and gut microbiomes. Further investigations to confirm the mechanisms that link the gut microbiome and metabolic alterations are necessary in the future.

Conclusion

The study suggests that a high-fat diet in ApoE-/- mice induces hyperlipidemia, rapid changes to crucial taxon in the gut microbiota, and significant differences in serum metabolite levels. After treatment with YNKB for 12 weeks, serum lipid profiles and disrupted gut microbiota structure were shown to be regulated. Oral administration of high-doses of YNKB resulted in significant lipid-lowering activity against hyperlipidemia in apoE-deficient mice, which might be associated with the composition alterations of the gut microbiota and changes in serum metabolite levels. These findings highlight that YNKB, as a medicine-food formulation derived from Sichuan dark tea, can prevent dyslipidemia and research can improve the understanding of its mechanisms and the pharmacological rationale for its preventive use.

Supporting information

S1 Table. The sixteen traditional Chinese herbs of YNKB.

(DOC)
Acknowledgments
This study was supported by the National Key R&D Program of China (2016YFC1305403) and the Sichuan Province Key R&D Program (2018FZ0104). We would like to thank Prof. Chuan Li, and the medicine-food tea from Chengdu YiNianKangBao Biological Technology Co., Ltd.

Author Contributions
Conceptualization: Martina Fu, Liang Ma, Ping Fu.
Data curation: Lingzhi Li, Fan Guo, Jing Liu, Yanhuan Feng.
Formal analysis: Lingzhi Li, Min Shi, Minghai Tang, Fan Guo, Jing Liu, Yanhuan Feng.
Funding acquisition: Liang Ma.
Investigation: Lingzhi Li, Min Shi, Fan Guo, Jing Liu, Qinwan Huang.
Methodology: Lingzhi Li, Minghai Tang, Qinwan Huang.
Resources: Min Shi.
Supervision: Liang Ma, Ping Fu.
Validation: Qinwan Huang, Liang Ma.
Visualization: Qinwan Huang.
Writing – original draft: Lingzhi Li.
Writing – review & editing: Stephen Salerno, Martina Fu, Liang Ma, Yi Li, Ping Fu.

References
1. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001; 104(4):503–16. PMID: 11239408
2. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond Cholesterol—Modifications Of Low-Density Lipoprotein That Increase Its Atherogeneity. New Engl J Med. 1989; 320(14):915–24. https://doi.org/10.1056/NEJM198904063201407 PMID: 2648148
3. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010; 340:c2197. https://doi.org/10.1136/bmj.c2197 PMID: 20488911
4. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005; 365(9468):1415–28. https://doi.org/10.1016/S0140-6736(05)66378-7 PMID: 15836891
5. du Souich P, Roederer G, Dufour R. Myotoxicity of statins: Mechanism of action. Pharmacol Ther. 2017; 175:1–16. https://doi.org/10.1016/j.pharmthera.2017.02.029 PMID: 28223230
6. Hou Y, Jiang JG. Origin and concept of medicine food homology and its application in modern functional foods. Food Funct. 2013; 4(12):1727–41. https://doi.org/10.1039/c3fo60295h PMID: 24100549
7. Diling C, Xin Y, Chaqun Z, Jian Y, Xiaocui T, Jun C, et al. Extracts from Hericium erinaceus relieve inflammatory bowel disease by regulating immunity and gut microbiota. Oncotarget. 2017; 8(49):85838–57. https://doi.org/10.18632/oncotarget.20689 PMID: 29156761
8. Huang Q, Chen S, Chen H, Wang Y, Wang Y, Hochstetter D, et al. Studies on the bioactivity of aqueous extract of pu-erh tea and its fractions: in vitro antioxidant activity and alpha-glycosidase inhibitory property, and their effect on postprandial hyperglycemia in diabetic mice. Food Chem Toxicol. 2013; 53:75–83. https://doi.org/10.1016/j.fct.2012.11.039 PMID: 23211442
A Sichuan dark tea formula improves hyperlipidemia

9. Lee LK, Foo KY. Recent advances on the beneficial use and health implications of Pu-erh tea. Food Res Int. 2013; 53(2):619–28.

10. Wang Y, Zhang M, Zhang Z, Lu H, Gao X, Yue P. High-theabrownins instant dark tea product by Aspergillus niger via submerged fermentation: alpha-glucosidase and pancreatic lipase inhibition and antiobesity activity. J Sci Food Agric. 2017; 97(15):5100–6. https://doi.org/10.1002/jsfa.8387 PMID: 2842292

11. Kubota K, Sumi S, Tojo H, Sumi-Inouye Y, HIC, OI Y, et al. Improvements of mean body mass index and body weight in preobese and overweight Japanese adults with black Chinese tea (Pu-erh) water extract. Nutr Res. 2011; 31(6):421–8. https://doi.org/10.1016/j.nutres.2011.05.004 PMID: 21745623

12. Shih CC, Lin CH, Lin YJ, Wu JB. Validation of the Antiatherosclerotic and Hypolipidemic Effects of Hawthorn by Assessment of Gluconeogenesis and Lipogenesis Related Genes and AMP-Activated Protein Kinase Phosphorylation. Evid Based Complement Alternat Med. 2013; 2013:597067. https://doi.org/10.1155/2013/597067 PMID: 23690849

13. Liao CH, Lin JY. Lotus (Nelumbo nucifera Gaertn) plumule polysaccharides ameliorate pancreatic islet loss and serum lipid profiles in non-obese diabetic mice. Food Chem Toxicol. 2013; 58:416–22. https://doi.org/10.1016/j.fct.2013.05.018 PMID: 23707471

14. Lin MC, Kao SH, Chung PJ, Chan KC, Yang MY, Wang CJ. Improvement for high fat diet-induced hepatic injuries and oxidative stress by flavonoid-enriched extract from Nelumbo nucifera leaf. J Agric Food Chem. 2009; 57(13):5925–32. https://doi.org/10.1021/jf901058a PMID: 19499892

15. Jiao Y, Wang X, Jiang X, Kong F, Wang S, Yan C. Antidiabetic effects of Morus alba fruit polysaccharides on high-fat diet- and streptozotocin-induced type 2 diabetes in rats. J Ethnopharmacol. 2017; 199:119–27. https://doi.org/10.1016/j.jep.2017.02.003 PMID: 28163112

16. Ono Y, Hattori E, Fukuya Y, Imai S, Ohizumi Y. Anti-obesity effect of Nelumbo nucifera leaves extract in mice and rats. J Ethnopharmacol. 2006; 106(2):238–44. https://doi.org/10.1016/j.jep.2005.12.036 PMID: 16495025

17. Huang JH, Huang XH, Chen ZY, Zheng QS, Sun RY. Dose conversion among different animals and healthy volunteers in pharmacological study. Chin J Clin Pharmacol Ther. 2004; 9:1069–72.

18. Shin HS, Han JM, Kim HG, Choi MK, Son CG, Yoo HR, et al. Anti-atherosclerosis and hyperlipidemia effects of herbal mixture, Artemisia iwayomogi Kitamura and Curcuma longa Linne, in apolipoprotein E-deficient mice. J Ethnopharmacol. 2014; 153(1):142–50. https://doi.org/10.1016/j.jep.2014.01.039 PMID: 24508858

19. Liu S, Li D, Huang B, Chen Y, Lu X, Wang Y. Inhibition of pancreatic lipase, alpha-glucosidase, amylase, and hypolipidemic effects of the total flavonoids from Nelumbo nucifera leaves. J Ethnopharmacol. 2013; 149(1):263–9. https://doi.org/10.1016/j.jep.2013.06.034 PMID: 23811214

20. Sugimoto M, Arai H, Tamura Y, Murayama T, Khaengkhun P, Nishio T, et al. Mulberry leaf ameliorates the expression profile of adipocytokines by inhibiting oxidative stress in white adipose tissue in db/db mice. Atherosclerosis. 2009; 204(2):388–94. https://doi.org/10.1016/j.atherosclerosis.2008.10.021 PMID: 19070857

21. Enkhmaa B, Shiwaku K, Katsube T, Kitajima K, Anuurad E, Yamasaki M, et al. Mulberry (Morus alba L.) leaves and their major flavonol quercetin 3-(6-malonylglucoside) attenuate atherosclerotic lesion development in LDL receptor-deficient mice. J Nutr. 2005; 135(4):729–34. https://doi.org/10.1093/jn/135.4.729 PMID: 15795425

22. Guo XF, Li ZH, Cai H, Li D. The effects of Lycium barbarum L. (L. barbarum) on cardiometabolic risk factors: a meta-analysis of randomized controlled trials. Food Funct. 2017; 8(5):1741–8. https://doi.org/10.1039/c7fo00183e PMID: 28401234

23. Li XM. Protective effect of Lycium barbarum polysaccharides on streptozotocin-induced oxidative stress in rats. Int J Biol Macromol. 2007; 40(5):461–5. https://doi.org/10.1016/j.ijbiomac.2006.11.002 PMID: 17166579

24. Li T, Li S, Dong Y, Zhu R, Liu Y. Antioxidant activity of penta-oligagalacturonic acid isolated from haw pectin, suppresses triglyceride synthesis in mice fed with a high-fat diet. Food Chem. 2014; 145:353–5. https://doi.org/10.1016/j.foodchem.2013.08.036 PMID: 24128486

25. Ye XL, Huang WW, Chen Z, Li XG, Li P, Lan P, et al. Synergistic effect and structure-activity relationship of 3-hydrox-3-methylglutaryl coenzyme A reductase inhibitors from Crataegus pinnatifida Bge. J Agric Food Chem. 2010; 58(5):3132–8. https://doi.org/10.1021/jf903337f PMID: 20171788

26. Gariouli L, Pomic C, Klopp P, Waget A, Charpentier J, Aloulou M, et al. The Gut Microbiota Regulates Intestinal CD4 T Cells Expressing RORgamma and Controls Metabolic Disease. Cell Metab. 2015; 22(1):100–12. https://doi.org/10.1016/j.cmet.2015.06.001 PMID: 26154056

27. Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermúdez-Humarán LG, et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med. 2011; 3(9):559–72. https://doi.org/10.1002/emmm.201100159 PMID: 21735552
28. Pomie C, Blasco-Baque V, Klopp P, Nicolas S, Waget A, Louibieres P, et al. Triggering the adaptive immune system with commensal gut bacteria protects against insulin resistance and dysglycemia. Mol Metab. 2016; 5(6):392–403. https://doi.org/10.1016/j.molmet.2016.03.004 PMID: 27257599

29. Henning SM, Yang J, Hsu M, Lee RP, Grojean EM, Ly A, et al. Decaffeinated green and black tea polyphenols decrease weight gain and alter microbiome populations and function in diet-induced obese mice. Eur J Nutr. 2017; 57(8):2759–69. https://doi.org/10.1007/s00394-017-1542-8 PMID: 28965248

30. Remely M, Aumuerller E, Merold C, Dworza k S, Hippe B, Zanner J, et al. Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity. Gene. 2014; 537(1):85–92. https://doi.org/10.1016/j.gene.2013.11.081 PMID: 24325907

31. Li L, Ma L, Fu P. Gut microbiota-derived short-chain fatty acids and kidney diseases. Drug Des Devel Ther. 2017; 11:3531–42. https://doi.org/10.2147/DDDT.S150825 PMID: 29270002

32. Alcock J, Maley CC, Aktipis CA. Is eating behavior manipulated by the gastrointestinal microbiota? Evolutionary pressures and potential mechanisms. Bioessays. 2014; 36(10):940–9. https://doi.org/10.1002/bies.201400071 PMID: 25103109

33. Ursell LK, Van Treuren W, Metcalf JL, Pirrung M, Gewirtz A, Knight R. Replenishing our defensive microbes. Bioessays. 2013; 35(9):810–7. https://doi.org/10.1002/bies.201300018 PMID: 23836415

34. Campbell CL, Yu R, Li F, Zhou Q, Chen D, Qi C, et al. Modulation of fat metabolism and gut microbiota by resveratrol on high-fat diet-induced obese mice. Diabetes Metab Syndr Obes. 2019; 12:97–107. https://doi.org/10.2147/DMSO.S192228 PMID: 30655683

35. Pauer H, Hardoim CCP, Teixeira FL, Miranda KR, Barbirato DDS, de Carvalho DP, et al. Impact of violacein from Chromobacterium violaceum on the mammalian gut microbiome. PLoS one. 2018; 13(9): e0203748. https://doi.org/10.1371/journal.pone.0203748 PMID: 30212521

36. Zhang C, Zhang M, Pang X, Zhao Y, Wang L, Zhao L. Structural resilience of the gut microbiota in adult mice under high-fat dietary perturbations. ISME J. 2012; 6(10):1848–57. https://doi.org/10.1038/ismej.2012.27 PMID: 22495068

37. Semova I, Carten Juliana D, Stombaugh J, Mackey Lantz C, Knight R, Farber Steven A, et al. Microbiota Regulate Intestinal Absorption and Metabolism of Fatty Acids in the Zebrafish. Cell Host & Microbe. 2012; 12(3):277–88. https://doi.org/10.1016/j.chom.2012.08.003 PMID: 22980325

38. Emoto T, Yamashita T, Sasaki N, Hirota Y, Hayashi T, So A, et al. Analysis of Gut Microbiota in Coronary Artery Disease Patients: a Possible Link between Gut Microbiota and Coronary Artery Disease. J Atheroscler Thromb. 2016; 23(8):908–21. https://doi.org/10.5551/jat.32672 PMID: 26947598

39. Backhed F, Ding H, Wang T, Hooper LV, Koh KY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004; 101(44):15718–23. https://doi.org/10.1073/pnas.1040707101 PMID: 15505215

40. Chen D, Yang Z, Chen X, Huang Y, Yin B, Guo F, et al. The effect of Lactobacillus rhamnosus hsr7ym 1301 on the intestinal microbiota of a hyperlipidemic rat model. BMC Complement Altern Med. 2014; 14:386. https://doi.org/10.1186/1472-6882-14-386 PMID: 25300818

41. Bernini LJ, Simao AN, Alfieri DF, Lozovoy MA, Mari NL, de Souza CH, et al. Beneficial effects of Bifidobacterium lactis on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial. Effects of probiotics on metabolic syndrome. Nutrition. 2016; 32(6):716–9. https://doi.org/10.1016/j.nut.2015.11.001 PMID: 27126957

42. Anhe FF, Roy D, Plion G, Dudonne S, Matamoros S, Varin TV, et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut. 2015; 64(6):872–83. https://doi.org/10.1038/gutjnl-2014-307142 PMID: 25080446

43. Axling U, Olsson C, Xu J, Fernandez C, Larsson S, Strom K, et al. Green tea powder and Lactobacillus plantarum affect gut microbiota, lipid metabolism and inflammation in high-fat fed C57BL/6J mice. Nutr Metab. 2012; 9(1):105. https://doi.org/10.1186/1743-7075-9-105 PMID: 23181558

44. Dao MC, Everal d A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2016; 65(3):426–36. https://doi.org/10.1136/gutjnl-2014-308778 PMID: 26100928

45. Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2014; 63(5):727–35. https://doi.org/10.1136/gutjnl-2012-303839 PMID: 23804561

46. Plovier H, Everal d A, Druart C, Depommier C, Van Hul M, Geurts L, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2017; 23(1):107–13. https://doi.org/10.1038/nm.4236 PMID: 27892954
47. Everard A, Belzer Clara., Geurts Lucie., Ouwerkerk, Janneke P., Druart Céline., Bindels, Laure B., . . . Cani, Patrice D. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013; 110(22):9066–71. https://doi.org/10.1073/pnas. 1219451110 PMID: 2367110

48. Galvez J, Rodriguez-Cabezas ME, Zarzuelo A. Effects of dietary fiber on inflammatory bowel disease. Mol Nutr Food Res. 2005; 49(6):601–8. https://doi.org/10.1002/mnfr.200500013 PMID: 15841496

49. Fan P, Liu P, Song P, Chen X, Ma X. Moderate dietary protein restriction alters the composition of gut microbiota and improves ileal barrier function in adult pig model. Sci Rep. 2017; 7:43412. https://doi. org/10.1038/srep43412 PMID: 28252026

50. Tomas J, Mulet C, Saffarian A, Cavin JB, Ducroc R, Regnault B, et al. High-fat diet modifies the PPAR-gamma pathway leading to disruption of microbial and physiological ecosystem in murine small intestine. Proc Natl Acad Sci U S A. 2016; 113(40):E5934–E43. https://doi.org/10.1073/pnas.1612559113 PMID: 27638207

51. Guo Y, Huang ZP, Li CQ, Qi L, Sheng Y, Zou DJ. Modulation of the gut microbiome: a systematic review of the effect of bariatric surgery. Eur J Endocrinol. 2018; 178(1):43–56. https://doi.org/10.1530/ EJE-17-0403 PMID: 28916564

52. Shao Y, Ding R, Xu B, Hua R, Shen Q, He K, et al. Alterations of Gut Microbiota After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy in Sprague-Dawley Rats. Obes Surg. 2017; 27(2):295–302. https://doi.org/10.1007/s11695-016-2297-7 PMID: 27440168

53. Del CF, Nobili V, Vernocchi P, Russo A, De SC, Gnani D, et al. Gut microbiota profiling of pediatric NAFLD and obese patients unveiled by an integrated meta-omics based approach. Hepatology. 2016; 65(2):451. https://doi.org/10.1002/hep.28572 PMID: 27028797

54. Xue S, Xiao W, Xinmin Y, Yuhua W, Min Z, Cuiqing Z, et al. Hepatic and fecal metabolomic analysis of the effects of Lactobacillus rhamnosus GG on alcoholic fatty liver disease in mice. J Proteome Res. 2015; 14(2):1174–82. https://doi.org/10.1021/pr501121c PMID: 25592873

55. Bahado-Singh RO, Ertl R, Mandal R, Bjorndahl TC, Syngellaki A, Han B, et al. Metabolic prediction of fetal congenital heart defect in the first trimester. Am J Obstet Gynecol. 2014; 211(3):240.e1–e14.

56. Kurano M, Kano K, Dohi T, Matsutoshi H, Igarashi K, Nishikawa M, et al. Different origins of lysosphospholipid mediators between coronary and peripheral arteries in acute coronary syndrome. J Lipid Res. 2017; 58(2):433–42. https://doi.org/10.1194/jlr.P071803 PMID: 28007846

57. Gonzalez E, Liempd SV, Conde- Vancells J, Juan GD, Perez-Cormenaza M, Mayo R, et al. Serum UPLC-MS/MS metabolic profiling in an experimental model for acute-liver injury reveals potential biomarkers for hepatotoxicity. Metabolomics. 2012; 8(6):997–1011. https://doi.org/10.1007/s11306-011-0329-9 PMID: 23139648

58. Cao G, DO C, M W, ND V, ZH Z, JR M, et al. Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression. Redox Biol. 2016; 10:168–78. https://doi.org/10.1016/j.redox.2016.09.014 PMID: 27750681

59. Thomas R, Barbara W, Caroline K, Nina L, Christian H, Ulrike H, et al. Changes in the serum metabolite profile in obese children with weight loss. Eur J Nutr. 2015; 54(2):173–81. https://doi.org/10.1007/ s00394-014-0698-8 PMID: 24740590

60. Cho K, Moon JS, Kang JH, Jang HB, Lee HJ, Park SI, et al. Combined untargeted and targeted metabolomic profiling reveals urinary biomarkers for discriminating obese from normal-weight adolescents. Pediatr Obes. 2016; 12(2):93. https://doi.org/10.1111/jpo.12114 PMID: 26910390

61. Seppänen-Laakso T, Sun D, Tang J, Ther man S, Viehman R, Mustonen U, et al. Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012; 4(1):1. https://doi.org/10.1186/gm300 PMID: 22257447